Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population. Methods: We described COVID-19 morbidity and mortali...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359231225028 |
| _version_ | 1827378321095131136 |
|---|---|
| author | Bruno Vincenzi Alessio Cortellini Alessandro Mazzocca Sarah Orlando Davide Romandini Juan Aguilar-Company Isabel Ruiz-Camps Claudia Valverde Morales Simeon Eremiev-Eremiev Carlo Tondini Joan Brunet Rossella Bertulli Salvatore Provenzano Mark Bower Daniele Generali Ramon Salazar Anna Sureda Aleix Prat Michalarea Vasiliki Mieke Van Hemelrijck Ailsa Sita-Lumsden Alexia Bertuzzi Sabrina Rossi Amanda Jackson Federica Grosso Alvin J. X. Lee Cian Murphy Katherine Belessiotis Uma Mukherjee Fanny Pommeret Angela Loizidou Gianluca Gaidano Gino M. Dettorre Salvatore Grisanti Marco Tucci Claudia A. M. Fulgenzi Alessandra Gennari Andrea Napolitano David J. Pinato |
| author_facet | Bruno Vincenzi Alessio Cortellini Alessandro Mazzocca Sarah Orlando Davide Romandini Juan Aguilar-Company Isabel Ruiz-Camps Claudia Valverde Morales Simeon Eremiev-Eremiev Carlo Tondini Joan Brunet Rossella Bertulli Salvatore Provenzano Mark Bower Daniele Generali Ramon Salazar Anna Sureda Aleix Prat Michalarea Vasiliki Mieke Van Hemelrijck Ailsa Sita-Lumsden Alexia Bertuzzi Sabrina Rossi Amanda Jackson Federica Grosso Alvin J. X. Lee Cian Murphy Katherine Belessiotis Uma Mukherjee Fanny Pommeret Angela Loizidou Gianluca Gaidano Gino M. Dettorre Salvatore Grisanti Marco Tucci Claudia A. M. Fulgenzi Alessandra Gennari Andrea Napolitano David J. Pinato |
| author_sort | Bruno Vincenzi |
| collection | DOAJ |
| description | Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population. Methods: We described COVID-19 morbidity and mortality among patients with STS across ‘Omicron’ (15 December 2021–31 January 2022), ‘Pre-vaccination’ (27 February 2020–30 November 2020), and ‘Alpha-Delta’ phase (01 December 2020–14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR 28 ) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders. Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18–92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR 28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR 28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR 28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR 28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis. Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population. |
| first_indexed | 2024-03-08T12:53:42Z |
| format | Article |
| id | doaj.art-c4bf349d60eb4e95af965b6c9b1f4f0c |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-03-08T12:53:42Z |
| publishDate | 2024-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-c4bf349d60eb4e95af965b6c9b1f4f0c2024-01-19T20:03:28ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-01-011610.1177/17588359231225028Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registryBruno VincenziAlessio CortelliniAlessandro MazzoccaSarah OrlandoDavide RomandiniJuan Aguilar-CompanyIsabel Ruiz-CampsClaudia Valverde MoralesSimeon Eremiev-EremievCarlo TondiniJoan BrunetRossella BertulliSalvatore ProvenzanoMark BowerDaniele GeneraliRamon SalazarAnna SuredaAleix PratMichalarea VasilikiMieke Van HemelrijckAilsa Sita-LumsdenAlexia BertuzziSabrina RossiAmanda JacksonFederica GrossoAlvin J. X. LeeCian MurphyKatherine BelessiotisUma MukherjeeFanny PommeretAngela LoizidouGianluca GaidanoGino M. DettorreSalvatore GrisantiMarco TucciClaudia A. M. FulgenziAlessandra GennariAndrea NapolitanoDavid J. PinatoBackground: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population. Methods: We described COVID-19 morbidity and mortality among patients with STS across ‘Omicron’ (15 December 2021–31 January 2022), ‘Pre-vaccination’ (27 February 2020–30 November 2020), and ‘Alpha-Delta’ phase (01 December 2020–14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR 28 ) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders. Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18–92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR 28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR 28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR 28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR 28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis. Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population.https://doi.org/10.1177/17588359231225028 |
| spellingShingle | Bruno Vincenzi Alessio Cortellini Alessandro Mazzocca Sarah Orlando Davide Romandini Juan Aguilar-Company Isabel Ruiz-Camps Claudia Valverde Morales Simeon Eremiev-Eremiev Carlo Tondini Joan Brunet Rossella Bertulli Salvatore Provenzano Mark Bower Daniele Generali Ramon Salazar Anna Sureda Aleix Prat Michalarea Vasiliki Mieke Van Hemelrijck Ailsa Sita-Lumsden Alexia Bertuzzi Sabrina Rossi Amanda Jackson Federica Grosso Alvin J. X. Lee Cian Murphy Katherine Belessiotis Uma Mukherjee Fanny Pommeret Angela Loizidou Gianluca Gaidano Gino M. Dettorre Salvatore Grisanti Marco Tucci Claudia A. M. Fulgenzi Alessandra Gennari Andrea Napolitano David J. Pinato Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry Therapeutic Advances in Medical Oncology |
| title | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry |
| title_full | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry |
| title_fullStr | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry |
| title_full_unstemmed | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry |
| title_short | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry |
| title_sort | impact of sars cov 2 vaccines and recent chemotherapy on covid 19 morbidity and mortality in patients with soft tissue sarcoma an analysis from the oncovid registry |
| url | https://doi.org/10.1177/17588359231225028 |
| work_keys_str_mv | AT brunovincenzi impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT alessiocortellini impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT alessandromazzocca impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT sarahorlando impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT davideromandini impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT juanaguilarcompany impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT isabelruizcamps impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT claudiavalverdemorales impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT simeoneremieveremiev impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT carlotondini impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT joanbrunet impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT rossellabertulli impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT salvatoreprovenzano impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT markbower impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT danielegenerali impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT ramonsalazar impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT annasureda impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT aleixprat impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT michalareavasiliki impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT miekevanhemelrijck impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT ailsasitalumsden impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT alexiabertuzzi impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT sabrinarossi impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT amandajackson impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT federicagrosso impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT alvinjxlee impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT cianmurphy impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT katherinebelessiotis impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT umamukherjee impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT fannypommeret impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT angelaloizidou impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT gianlucagaidano impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT ginomdettorre impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT salvatoregrisanti impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT marcotucci impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT claudiaamfulgenzi impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT alessandragennari impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT andreanapolitano impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry AT davidjpinato impactofsarscov2vaccinesandrecentchemotherapyoncovid19morbidityandmortalityinpatientswithsofttissuesarcomaananalysisfromtheoncovidregistry |